Results of a phase I/II trial of amrubicin (AMR) in combination with cisplatin (CDDP) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC).
暂无分享,去创建一个
Y. Ichinose | M. Fukuoka | N. Masuda | K. Kaira | N. Yamamoto | T. Seto | T. Hida | K. Takeda | S. Negoro | S. Yokota